Sarepta Therapeutics has halted distribution of its gene therapy, Levitas, for advanced Duchenne muscular dystrophy patients after a second patient died from liver failure.
BreakdownGenerated by LeadStory AI
- A second patient has died after receiving Sarepta's gene therapy for Duchenne muscular dystrophy. 4s
- Both deceased patients were teenagers who could no longer walk, a group recently included in the therapy's approval. 34s
- The FDA had controversially expanded Levitas' approval to nearly all Duchenne patients last year. 45s
- Sarepta has halted shipments of the therapy for advanced patients and is reviewing safety protocols. 1m 1s
- Sarepta has suspended its 2025 financial guidance and its stock has dropped sharply. 1m 7s